BlackBerry is a company that makes phones and other things, but their stocks are worth less now because they want to borrow money from some people. This makes people worried, so they sell their BlackBerry shares for cheaper prices. Other companies have different stories happening today, like Annovis Bio getting more money or Evaxion Biotech having a big partner. Read from source...

- The title is misleading and sensationalized. It implies that BlackBerry shares are trading lower by over 17% because of some specific event or news, but the article does not provide any evidence or explanation for this causality. A better title would be "BlackBerry Shares Drop By Over 17%, Other Stocks Moving In Wednesday's Session".
- The first paragraph is confusing and poorly written. It mentions a proposed private offering of $160 million of convertible senior notes, but does not explain what this means or why it would affect the share price negatively. A more clear and informative paragraph would be "The company announced a planned financing round of $160 million through the issuance of convertible senior notes, which are debt securities that can be exchanged for common stock in the future. This could indicate that the company is seeking to raise capital or refinance its existing debt, but it also dilutes the ownership and value of existing shareholders."
- The second paragraph is irrelevant and filler content. It lists other stocks moving in Wednesday's session without any context or analysis. There is no reason for readers to care about these stocks unless they are related to BlackBerry or have some significance for the market or investors. A more useful paragraph would be "Some possible factors that could influence the market today include the announcement of a new debt facility by Annovis Bio, which boosted its share price, and the disclosure of a stake in Evaxion Biotech by Merck & Co, which increased interest in the biotechnology company."

- BlackBerry: sell (high risk, high reward) - Annovis Bio: buy (low risk, moderate reward) - Evaxion Biotech A/S: hold (moderate risk, high reward potential) - SciSparc Ltd.: hold (moderate risk, high reward potential)